Ad Code

ICH Quality Guidelines Q1–Q14: Complete Master Guide

Shahzaib Aftab September 21, 2026
ICH Quality Guidelines Q1–Q14: Complete Master Guide | Web of Pharma
ICH Quality • Master Reference

ICH Quality Guidelines Q1–Q14

A structured master hub covering the International Council for Harmonisation (ICH) Quality guideline family—from stability and impurities to pharmaceutical development, quality risk management, lifecycle management, continuous manufacturing, and analytical procedure development.

14 Quality families Guidelines + annexes + Q&As + training Pharmaceutical development & GMP focused Searchable master index
Regulatory note: This page is an educational index. Always confirm the latest guideline version, implementation status, regional requirements, and official documents directly from ICH and the applicable regulatory authority.

What are ICH Quality Guidelines?

ICH Quality Guidelines harmonise key technical expectations for pharmaceutical quality across major regulatory systems. They address how drug substances and drug products are developed, tested, manufactured, controlled, evaluated and managed throughout their lifecycle.

DevelopmentPharmaceutical development, analytical procedure development, specifications, stability and impurity control.
Manufacturing & GMPAPI GMP, quality systems, risk management, lifecycle controls and continuous manufacturing.
Regulatory harmonisationCommon scientific principles that support consistent quality assessment and global submissions.
No matching ICH Quality guideline was found. Try a different keyword or guideline code.
Q1
StabilityStability study design, photostability, bracketing/matrixing and data evaluation
+
Q1A(R2)
Stability Testing of New Drug Substances and Products
Guideline
Q1B
Photostability Testing of New Drug Substances and Products
Guideline
Q1C
Stability Testing for New Dosage Forms
Guideline
Q1D
Bracketing and Matrixing Designs for Stability Testing
Guideline
Q1E
Evaluation of Stability Data
Guideline
Q1F
Stability Data Package for Climatic Zones III and IVICH withdrew Q1F; climatic-zone III/IV storage conditions are addressed by relevant regions and WHO guidance.
Withdrawn
Q1 EWG
Stability Testing of Drug Substances and Drug ProductsModernisation/revision work covering the stability guideline framework.
Under development
Q2
Analytical ValidationValidation principles for analytical procedures
+
Q2(R2)
Validation of Analytical Procedures
Guideline
Q2(R2)/Q14
Training on Validation of Analytical Procedures and Analytical Procedure Development
Training
Q3
ImpuritiesOrganic impurities, residual solvents, elemental impurities, extractables and leachables
+
Q3A(R2)
Impurities in New Drug Substances
Guideline
Q3B(R2)
Impurities in New Drug Products
Guideline
Q3C(R9)
Residual Solvents
Guideline
Q3C(R10)
Maintenance of the Residual Solvents Guideline
Maintenance
Q3D(R2)
Elemental Impurities
Guideline
Q3D(R3)
Maintenance of the Elemental Impurities Guideline
Maintenance
Q3D Training
Implementation of the Elemental Impurities Guideline
Training
Q3E EWG
Extractables and LeachablesDeveloping a harmonised framework for assessment and control of leachable impurities.
Under development
Q4
PharmacopoeiasPharmacopoeial harmonisation and evaluation of general test chapters
+
Q4A
Pharmacopoeial Harmonisation
Guideline
Q4B
Evaluation and Recommendation of Pharmacopoeial Texts
Guideline
Q4B(R1)
Revision of Q4B Framework
Revision
Annex 1(R1)
Residue on Ignition / Sulphated Ash
Annex
Annex 2(R1)
Extractable Volume of Parenteral Preparations
Annex
Annex 3(R1)
Sub-Visible Particles
Annex
Annex 4A(R1)
Microbial Enumeration Tests
Annex
Annex 4B(R1)
Tests for Specified Micro-Organisms
Annex
Annex 4C(R1)
Microbiological Acceptance Criteria
Annex
Annex 5(R1)
Disintegration Test
Annex
Annex 6
Uniformity of Dosage Units
Annex
Annex 7(R2)
Dissolution Test
Annex
Annex 8(R1)
Sterility Test
Annex
Annex 9(R1)
Tablet Friability
Annex
Annex 10(R1)
Polyacrylamide Gel Electrophoresis
Annex
Annex 11
Capillary Electrophoresis
Annex
Annex 12
Analytical Sieving
Annex
Annex 13
Bulk Density and Tapped Density of Powders
Annex
Annex 14
Bacterial Endotoxins Test
Annex
Q4B FAQs
Questions and Answers / Frequently Asked Questions
Q&A
Q5
Quality of Biotechnological ProductsViral safety, expression constructs, cell substrates, stability and comparability
+
Q5A(R2)
Viral Safety Evaluation
Guideline
Q5B
Analysis of the Expression Construct
Guideline
Q5C
Stability Testing of Biotechnological / Biological Products
Guideline
Q5D
Derivation and Characterisation of Cell Substrates
Guideline
Q5E
Comparability of Biotechnological / Biological Products
Guideline
Q5E Annex EWG
Comparability of Advanced Therapy Medicinal Products (ATMPs) Subject to Manufacturing Process Changes
Under development
Q6
SpecificationsTest procedures and acceptance criteria for chemical and biological products
+
Q6A
Specifications for Chemical Substances
Guideline
Q6B
Specifications for Biotechnological / Biological Products
Guideline
Q6(R1) EWG
Revision of Specifications Guidelines
Under development
Q7
Good Manufacturing PracticeGMP for active pharmaceutical ingredients
+
Q7
GMP Guide for Active Pharmaceutical Ingredients
Guideline
Q7 Q&As
Questions and Answers on Good Manufacturing Practice for APIs
Q&A
Q8
Pharmaceutical DevelopmentScience- and risk-based pharmaceutical development and design space concepts
+
Q8(R2)
Pharmaceutical Development
Guideline
Q8/Q9/Q10
Implementation of Pharmaceutical Development, Quality Risk Management and Pharmaceutical Quality System
Implementation
Q9
Quality Risk ManagementPrinciples and tools for science- and risk-based quality decisions
+
Q9(R1)
Quality Risk Management
Guideline
Q9(R1) IWG
Training on Quality Risk Management
Training
Q8/Q9/Q10
Implementation
Implementation
Q10
Pharmaceutical Quality SystemLifecycle pharmaceutical quality management model
+
Q10
Pharmaceutical Quality System
Guideline
Q8/Q9/Q10
Implementation
Implementation
Q11
Development and Manufacture of Drug SubstancesDrug-substance process development, control strategy and starting materials
+
Q11
Development and Manufacture of Drug Substances
Guideline
Q11 Q&As
Selection and Justification of Starting Materials
Q&A
Q12
Lifecycle ManagementTechnical and regulatory management of post-approval product changes
+
Q12
Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
Guideline
Q12 Training
Training on Pharmaceutical Product Lifecycle Management
Training
Q13
Continuous ManufacturingDevelopment, implementation, operation and lifecycle management of continuous manufacturing
+
Q13
Continuous Manufacturing of Drug Substances and Drug Products
Guideline
Q13 Training
Training on Continuous Manufacturing
Training
Q14
Analytical Procedure DevelopmentScience- and risk-based development of analytical procedures
+
Q14
Analytical Procedure Development
Guideline
Q2(R2)/Q14
Training on Validation of Analytical Procedures and Analytical Procedure Development
Training

Important current-development items

Several Quality topics are being revised, maintained or expanded. Treat draft/EWG items separately from final harmonised guidelines.

Q1 EWGBroader stability guideline modernisation.
Q3E EWGExtractables and leachables framework under development.
Q5E Annex EWGATMP comparability after manufacturing changes.
Q6(R1) EWGRevision of specifications guidance.

Frequently Asked Questions

What do ICH Quality Guidelines cover?

They cover pharmaceutical quality topics such as stability, analytical validation and development, impurities, pharmacopoeial harmonisation, biotechnology products, specifications, API GMP, pharmaceutical development, quality risk management, pharmaceutical quality systems, drug-substance development, lifecycle management and continuous manufacturing.

Which ICH guideline covers GMP for active pharmaceutical ingredients?

ICH Q7 is the Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, supported by a Q&A document for implementation and interpretation.

Which ICH guidelines cover analytical methods?

ICH Q2(R2) addresses validation of analytical procedures, while ICH Q14 addresses analytical procedure development. ICH also provides combined Q2(R2)/Q14 training materials.

Is ICH Q1F still an active guideline?

No. ICH Q1F was withdrawn. Stability requirements for climatic zones III and IV should be checked against current WHO guidance and applicable regional requirements.

How should this master page be used?

Use it as a navigation and learning hub. Each guideline can later be linked to a dedicated Web of Pharma article, summary, checklist, training page or official ICH reference.

Shahzaib Aftab

Posted by Shahzaib Aftab

Shahzaib Aftab is a leading pharmaceutical blogger and author from Pakistan, and the founder of webofpharma.com, a trusted pharmaceutical knowledge platform serving professionals since 2018. He is committed to simplifying complex pharmaceutical standards, regulatory requirements, and pharmacopeial knowledge for students and industry professionals worldwide.